FDA Proposes Doing Away With Biosimilar Switching Studies for Interchangeability
-
Jul 11, 2024
When the biosimilar pathway was first established, it created a two-tier system of biosimilars and interchangeable biosimilars, but multiple attempts have been made recently to level the playing field. In the latest move, the FDA proposed doing away with switching studies for interchangeables. But while the move could bring biosimilars onto the U.S. market faster and result in more competition, industry efforts are divided about whether it could prompt broader payer uptake.
As part of the Affordable Care Act (ACA), the Biologics Price Competition and Innovation Act of 2009 (BPCIA) amended the Public Health Service (PHS) Act and established section 351(k), which outlines the requirements for a proposed biosimilar product and a proposed interchangeable biosimilar product. Physicians must specifically prescribe biosimilars without interchangeable status, but when a biosimilar is approved as interchangeable, that drug may be substituted at the site of care or dispensing for its reference product by a dispensing pharmacist or practitioner without the involvement of the prescribing physician.
Read more
© 2024 MMIT
Related Posts
-
![]()
Jul 11
Biosimilars Market Is Becoming More Active but Still Faces Issues
Read more -
![]()
Apr 11
Budgets Propose Eliminating Interchangeability Status for Biosimilars
Read more -
![]()
Nov 09
FDA Draft Guidance Could Diminish Significance of Interchangeable Biosimilars While Promoting Use of All Biosimilars
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.